+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

R

Actively Recruiting

This trial investigates the use of ivonescimab compared to pembrolizumab as first-line treatments for patients with metastatic non-small cell lung cancer NSCLC whose tumors show high PD-L1 expression. The study focuses on evaluating overall survival and progression-free survival, aiming to understand how these treatments affect disease outcomes in this specific group. Participants will be randomly assigned to receive either ivonescimab or pembrolizumab as intravenous injections. Both treatments are administered as part of a double-blinded, phase 3 study, with a treatment period that may continue while monitoring the patients response and survival for up to approximately 36 months. Throughout the study, participants will undergo regular assessments including measurements of survival, disease progression, response rates, and monitoring for adverse events and laboratory abnormalities. Researchers will collect data on the duration of response and disease control, with safety follow-up continuing up to 30 to 90 days after the last treatment dose or initiation of other anticancer therapies. The overall study period extends until June 2029.

Age: 18Years +All GendersPhase 3
285 locations
O

Actively Recruiting

Researchers are evaluating how well cabozantinib works and how safe it is for adults with neuroendocrine tumors NETs, a type of cancer that can appear in various parts of the body. This study is focused on adults whose disease has continued to grow despite receiving at least one prior systemic treatment. The study takes place in regular hospitals and clinics in Germany and Austria and involves about 150 participants. Participants in this observational study will be taking cabozantinib as part of their usual care. No extra tests or procedures beyond routine medical visits, tests, and scans will be performed. Doctors will collect information on how the cancer responds to cabozantinib and how long participants stay on the treatment, along with monitoring side effects and quality of life. During the study, participants will be observed through their standard medical care visits. Researchers will gather data from routine medical tests, scans, and questionnaires about quality of life every three months for up to 18 months. They will measure disease control rates at 6 months, treatment duration, adverse events, and other clinical outcomes. The total follow-up period can last up to 18 months to monitor disease progression and treatment impact.

Age: 18Years +All Genders
41 locations